Daily pill doubles survival in deadliest cancer trial, experts say
4 reported
A daily pill has been shown to double survival time in patients with the world’s deadliest cancer, according to results from a clinical trial. Experts have described the findings as a gamechanger and one of the biggest breakthroughs in decades. The treatment, called daraxonrasib, was discussed by Prof Naureen Starling, a consultant medical oncologist at the Royal Marsden hospital, in a podcast interview with The Guardian. The interview focused on how the drug works and its potential impact on patients. The report is based on a single source, The Guardian, and has not been independently confirmed.
What’s reported
A daily pill can double survival time in patients with the world’s deadliest cancer, according to clinical trial results.
Experts called the findings a gamechanger and one of the biggest breakthroughs in decades.
The drug is named daraxonrasib.
Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital, discussed the treatment in a podcast.
Key figures
Prof Naureen Starling, consultant medical oncologist at the Royal Marsden hospital
Sources: The Guardian
